11th PACTRIMS Congress Themes:

  1. The Future of B-Cell Therapies in MS and NMOSD
  2. Targeting the Innate Immune System in PMS
  3. Development and Use of Biomarkers
  4. MRI Measures of Atrophy in the Clinic
Thursday, 1 November 2018
Grand Ballroom, Level B
13:00-14:30 European Charcot Foundation Symposium
14:30-15:00 Coffee Break
15:00-15:15 Opening Ceremony
15:15-17:10 Opening Lecture Series
Immune Mechanisms and Next Generation Therapies of MS and NMOSD
Opening Lecture-1
1. Landscape of B Cell Therapies and Possible Mechanisms of Action in MS
Opening Lecture-2
2. Risks of Sustained B Cell Depletion
– Sean Riminton (Australia)
Opening Lecture-3
3. Emerging Treatment for NMOSD Based on Immune Mechanisms
17:10-17:30 Coffee Break
17:30-19:00 Merck Sponsored Symposium
19:30-21:00 Welcome Reception


Friday, 2 November 2018
Grand Ballroom, Level B
08:00-09:30 Sanofi Genzyme Sponsored Symposium
09:30-10:00 Coffee Break
10:00 -11:30 Main Symposium-1
Surrogate Markers for Monitoring MS and NMOSD Disease Activity, Treatment Response, and Outcomes
1. Do Biomarkers Beget Better Biomarkers? (Serum and CSF Biomarkers)
2. Do Clinicians Need to Monitor Atrophy Rates and What Factors Limit the Measurement of Atrophy Rates in the Clinic
3. Passive and Active Monitoring Applications and Devices
– Helmut Butzkueven (Australia)
4. Artificial Intelligence in the Monitoring and Management of MS
– Fu-Dong Shi (China)
11:30-12:40 Oral Presentation
12:40-13:40 Lunch
13:40-14:20 11th PACTRIMS Presidential Invited Lecture
Innate Immune System-Mediated Mechanisms of action in Progressive MS: How to Target Innate Immunity in the Future
14:20-14:50 Two Minute Oral Presentation of Selected Posters
14:50-15:10 Coffee Break
15:10-17:10 Main Symposium-2
Educational Seminars: Comprehensive Management of MS and NMOSD in Asia-Pacific Regions
1. Practical Issues in the Management of Relapsing Inflammatory CNS Disease in Asia-Pacific Regions
– Shanthi Viswanathan (Malaysia)
2. Aggressive MS & NMOSD: How to Define and How to Manage It
– Ho Jin Kim (Republic of Korea)
3. The Approach to the Management of Indeterminate MS/NMOSD
– Kazuo Fujihara (Japan)
4. Symptomatic Management of MS: What Works and What Doesn’t
– Simon Broadley (Australia)
17:10-17:30 Coffee Break
17:30-19:00 Biogen Sponsored Symposium
20:00-22:30 Presidential Dinner


Friday, 2 November 2018
Heritage Room, Level G (Breakout Session)
15:20-17:20 Main Symposium-3
Workshop: Potential Biomarkers Related to Mechanism of Inflammatory CNS Demyelinating Disease in Asians
1. CSF Biomarkers for NMOSD
– Shuhei Nishiyama (Japan)
2. Gamma Delta T Cells are Associated with Disability Progression in MS
– Noriko Isobe (Japan)
3. OCT and Eye Movements
– Owen White (Australia)


Saturday, 3 November 2018
Grand Ballroom, Level B
08:00-09:30 Roche Sponsored Symposium
09:30-10:00 Coffee Break
10:00-12:00 Main Symposium-4
New MRI Technology and Signs Disclose Pathology and Differentiation of MS and NMOSD
1. MRI Signs that Differentiate NMOSD from MS
– Yaou Liu (China)
2. Central Vein Sign Differentiates MS from CNS Vasculitis
3. T1/T2-Weighted Ratio Disclose Cortical Pathology in MS
4. MRI Neurography Reveals Peripheral Nerve Involvement in MS
12:00-12:15 Closing and Award Ceremony


*subject to change